Regulatory Pathways Of Compensatory Left Ventricular Hypertrophy
Funder
National Health and Medical Research Council
Funding Amount
$309,536.00
Summary
An increase in muscle bulk (hypertrophy) of the major pumping chamber of the heart, the left ventricle, occurs as a compensatory mechanism to maintain cardiac function in a wide variety of common cardiovascular diseases, such as hypertension. Nevertheless, this compensatory mechanism appears to be strongly associated with an increased risk of death from cardiovascular disease. Consequently, the prevention or reversal of left ventricular hypertrophy is one of the major goals of the treatment of p ....An increase in muscle bulk (hypertrophy) of the major pumping chamber of the heart, the left ventricle, occurs as a compensatory mechanism to maintain cardiac function in a wide variety of common cardiovascular diseases, such as hypertension. Nevertheless, this compensatory mechanism appears to be strongly associated with an increased risk of death from cardiovascular disease. Consequently, the prevention or reversal of left ventricular hypertrophy is one of the major goals of the treatment of patients with cardiovascular disease. This project aims to improve our understanding of the complex chemical messengers in the heart muscle that control the development of hypertrophy to provide a basis for more specific drug treatments to control this process, with the aim of reducing the morbidity and mortality associated with hypertrophy.Read moreRead less
A Controlled Longitudinal Study Of Knee Cartilage Volume If The Offspring Of Subjects With Osteoarthritis Of The Knee.
Funder
National Health and Medical Research Council
Funding Amount
$144,392.00
Summary
Osteoarthritis is the most common cause of musculoskeletal disability and cost in Australia. Both genetic and environmental factors have been implicated as causes of this disease. As yet, however, there are no proven strategies for prevention of this very common condition and treatment of established disease is unsatisfactory. Part of the reason for this is the fact that there is no sensitive and accurate measure of early disease. In this study, we plan to evaluate knee cartilage volume assessed ....Osteoarthritis is the most common cause of musculoskeletal disability and cost in Australia. Both genetic and environmental factors have been implicated as causes of this disease. As yet, however, there are no proven strategies for prevention of this very common condition and treatment of established disease is unsatisfactory. Part of the reason for this is the fact that there is no sensitive and accurate measure of early disease. In this study, we plan to evaluate knee cartilage volume assessed by magnetic resonance imaging. This is a promising new candidate which is both accurate and sensitive. We will be measuring knee volume both cross-sectionally and longitudinally in the offspring of patients who have had knee replacement for osteoarthritis and comparing them to randomly selected controls to see if knee volume can be utilised as a marker of early or asymptomatic disease particularly in identifying which treatments may be effective at preventing osteoarthritis in later life.Read moreRead less
Using Nanotechnology To Improve The Therapeutic Efficacy Of Iron Chelators
Funder
National Health and Medical Research Council
Funding Amount
$692,769.00
Summary
Iron loading disorders (such as thalassaemia) represent an important class of human disease. As part of the treatment for these diseases, the iron needs to be removed and this is often done using iron-binding drugs known as iron chelators. Current chelators are not ideal due to side effects or onerous delivery methods. The goal of this project is to use nanotechnology to develop more effective ways of delivering chelators to improve their effectiveness and reduce toxicity.
Iron Overload Mechanisms In Dyserythropoietic Anaemias And Therapeutic Targets At The ERFE Gene Locus
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Iron overload causes organ dysfunction and morbidity for people who have red blood cell disorders such as thalassemia, or chronic transfusion requirements due to cancer or bone marrow failure. The manner in which a principal controlling compound, erythroferrone, influences iron metabolism is undefined. Our project will use molecular approaches to determine how the erythroferrone gene is involved in causing iron overload in red cell disorders and potentially open better management pathways.